Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center

Purpose In 2016, we initiated standardized “reflex” Oncotype DX Recurrence Score (RS) testing for patients ≤ 65 years with pT1-2N0-1 HR + /HER2 − breast cancer. Here, we examine RS testing patterns, RS distribution, and factors associated with chemotherapy use in patients with pN1 breast cancer. Met...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research and treatment 2021, Vol.185 (1), p.215-227
Hauptverfasser: Losk, Katya, Freedman, Rachel A., Laws, Alison, Kantor, Olga, Mittendorf, Elizabeth A., Tan-Wasielewski, Zhenying, Trippa, Lorenzo, Lin, Nancy U., Winer, Eric P., King, Tari A.
Format: Artikel
Sprache:eng
Schlagworte:
Adjuvant treatment
Breast cancer
Cancer
Cancer research
Chemotherapy
Comparative analysis
Epidemiology
ErbB-2 protein
Medicine
Medicine & Public Health
Multivariate analysis
Oncology
Patients
Surgery
Survival
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose In 2016, we initiated standardized “reflex” Oncotype DX Recurrence Score (RS) testing for patients ≤ 65 years with pT1-2N0-1 HR + /HER2 − breast cancer. Here, we examine RS testing patterns, RS distribution, and factors associated with chemotherapy use in patients with pN1 breast cancer. Methods Patients with stage I–III HR + /HER2 − pN1 breast cancer treated with upfront surgery from February 2016 to March 2019 were identified. Clinical characteristics were compared between patients meeting reflex RS testing criteria, those with RS ordered outside of reflex criteria, and those without RS testing. RS was categorized as low (
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-020-05931-9